This approach has proven efficacy, although often transient, in slowing disease progression and preserving residual beta cell function, particularly in recent-onset type 1 diabetes (sources for the efficacy of immunotherapy, e.g., from the Teplizumab trials)
This product page is designed to help research customers review product details, related compounds, handling guidance, and research classification in one organized format
Injectable Therapeutic PeptidesAn Adjunct to Regenerative Medicine and Sports Performance
In some embodiments, the formulations or compositions described herein have a pH and osmolarity as described herein, and have a concentration of active pharmaceutical ingredient between about 0.01-about 20%, between about 0.01-about 10%, between about 0.01-about 7%, between about 0.01-5%, between about 0.01-about 3%, between about 0.01-about 2% of the active ingredient by weight of the formulation or composition